Acetylon Pharmaceuticals Inc. is developing next-generation selective small molecule histone deacetylase (HDAC) inhibitors and other targeted drugs for the treatment of cancers as well as inflammatory, neurodegenerative, genetic and infectious diseases. Selective HDAC inhibitors have the potential to reduce or eliminate the substantial side effects observed with current non-selective approaches while also realizing their extraordinary potential for enhanced therapeutic benefit through higher dosing, extended administration and reduction of combination drug toxicity. Selective HDAC inhibitors also have potential for improved therapeutic benefit in autoimmune and other inflammatory disorders, neurodegenerative diseases and certain genetic and infectious diseases.

Financials

People